RETRACTED ARTICLE: Upregulation of microRNA-204 improves insulin resistance of polycystic ovarian syndrome via inhibition of HMGB1 and the inactivation of the TLR4/NF-κB pathway

Jiang, Bin; Xue, Min; Xu, Dabao; Song, Yujia; Zhu, Shaojun

doi:10.1080/15384101.2020.1724601

Cited by 14 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have demonstrated that HMGB1 could trigger the TLR4 signaling pathway and NF-κB activation, thereby inducing the expression of inflammatory factors ( 34 , 35 ). Jiang et al ( 18 ) suggested that inhibition of HMGB1 could improve IR in PCOS through the suppression of the TLR4/NF-κB pathway. To determine whether CRY could reverse PCOS by regulating HMGB1/TLR4/NF-κB signaling, the expression of these IR-related markers were evaluated in ovarian tissue and GCs.…”

Section: Discussionmentioning

confidence: 99%

“…Our previous study suggested an association between high-mobility group box 1 protein (HMGB1) and IR in PCOS ( 8 ). A previous study demonstrated that inhibition of HMGB1 could improve IR in PCOS by suppressing the toll-like receptor (TLR)4/NF-κB signaling pathway ( 18 ). Therefore, it was hypothesized that CRY may serve a therapeutic role in PCOS by regulating the HMGB1/TLR4/NF-κB signaling pathway.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

Yang

Cao

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

cryptotanshinone (crY) has been demonstrated to reverse reproductive disorders. However, whether crY is effective in the treatment of polycystic ovary syndrome (PcoS) remains unknown. The aim of the present study was to evaluate the therapeutic potential of crY in PcoS. a rat model of PcoS was established by daily injection of human chorionic gonadotropin and insulin for 22 days. Total body weight and ovarian weight, as well as the levels of luteinizing hormone (lH) and the lH to follicle-stimulating hormone (FSH) ratio (LH/FSH) significantly increased in rats with PCOS, compared with controls. Moreover, the levels of testosterone (T), tumor necrosis factor (TnF)-α and high-mobility group box 1 protein (HMGB1) also increased. However, crY treatment attenuated the increase in body weight, ovarian weight, lH, lH/FSH ratio, T, TnF-α and HMGB1 levels, compared with the PcoS group. Treatment with crY also reduced NF-κB/p65, HMGB1 and toll-like receptor (TLR)4 mrna and protein expression levels in the ovarian tissue and granulosa cells, both in vitro and in vivo. Thus, CRY significantly mitigated the changes in body weight, ovary weight, hormone levels and inflammatory factor levels observed in rats with PcoS. Thus, crY protects against PcoS-induced damage of ovarian tissue, possibly through a regulatory pathway involving HMGB1, Tlr4 and nF-κB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

Yang

Cao

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) are ~22nt long small and non-coding RNAs that directly target the 3′-UTR region of mRNAs, thus affecting mRNA transcription and translation [ 5 , 6 ]. miRNAs have been reported to have essential functions in metabolic disorders, including PCOS [ 7 – 9 ]. Specifically, miR-206 promotes LPS-induced inflammation and release of amyloid-beta by targeting IGF1 in microglia [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor

Lin

et al. 2021

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) is an endocrine-related follicular developmental disorder that affects 50 %-70 % of reproductive-aged women diagnosed with ovulation-related infertility. Abnormal proliferation and apoptosis of granulosa cells (GCs) are thought to be the critical factors leading to abnormal maturation of follicles. It has been shown that microRNAs (miRNAs) exert a significant influence in the pathogenesis of PCOS; however, the relationship between miRNA, PCOS, and GC apoptosis is not entirely understood. Methods To clarify the effect of miR-194 in PCOS, CCK-8, Ki67 staining, AO/EB, and flow cytometry assays were used to assess cell growth, proliferation, and apoptosis in KGN cells, which were artificially stimulated to overexpress miR-194. Luciferase reporter assays and rescue experiments were used to elucidate the mechanism underlying miR-194 in PCOS. Results miR-194 expression was significantly up-regulated in rat models of PCOS and the ovarian GCs of PCOS patients. miR-194 suppression promoted KGN cell growth and proliferation. miR-194 overexpression also induced cell apoptosis, while miR-194 downregulation had an opposite effect. Furthermore, up-regulating heparin-binding EGF-like growth factor (HB-EGF) expression rescued the pro-apoptotic effects of miR-194 upregulation on KGN cells. Conclusions miR-194 is increased in PCOS granulosa cell and may function as a novel biomarker and therapeutic target for KGN cells via HB-EGF regulation.

show abstract

“… Yang et al (2020) found that cryptotanshinone (CRY) significantly alleviated the changes in the body and ovary weight, and the levels of hormone and inflammatory factor in PCOS rats through regulating the HMGB1/TLR4/nuclear factor-kappa B (NF- κ B) signaling pathway. Furthermore, the upregulation of miR-204 improved IR of PCOS via the inhibition of HMGB1 and inactivation of the TLR4/NF-κB pathway ( Jiang et al, 2020 ), while increased HMGB1 and reduced FOXO1 were found to be dependent on the loss of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) function in case of CF ( Smerieri et al, 2014 ; Montanini et al, 2016b ; Cirillo et al, 2019b ).…”

Section: Introductionmentioning

confidence: 99%

Involvement of Transcription Factor FoxO1 in the Pathogenesis of Polycystic Ovary Syndrome

Wang

2021

Front. Physiol.

View full text Add to dashboard Cite

FoxO1 is a member of the forkhead transcription factor family subgroup O (FoxO), which is expressed in many cell types, and participates in various pathophysiological processes, including cell proliferation, apoptosis, autophagy, metabolism, inflammatory response, cytokine expression, immune differentiation, and oxidative stress resistance. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in the women of childbearing age, which is regulated via a variety of signaling pathways. Currently, the specific mechanism underlying the pathogenesis of PCOS is still unclear. As an important transcription factor, FoxO1 activity might be involved in the pathophysiology of PCOS. PCOS has been associated with insulin resistance and low-grade inflammatory response. Therefore, the studies regarding the role of FoxO1 in the incidence and associated complications of PCOS will help provide novel ideas for establishing the treatment strategy of PCOS.

show abstract

RETRACTED ARTICLE: Upregulation of microRNA-204 improves insulin resistance of polycystic ovarian syndrome via inhibition of HMGB1 and the inactivation of the TLR4/NF-κB pathway

Cited by 14 publications

References 41 publications

Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway

microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor

Involvement of Transcription Factor FoxO1 in the Pathogenesis of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About